Comenzo, R L <br/><br/>
Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.  [electronic resource] 

 -  Blood  May 1998 
 - 3662-70 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>0006-4971 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Amyloidosis--drug therapy<br/>Antineoplastic Agents, Alkylating--administration & dosage<br/>Cohort Studies<br/>Combined Modality Therapy<br/>Erythrocyte Transfusion<br/>Female<br/>Hematopoietic Stem Cell Transplantation--adverse effects<br/>Humans<br/>Kidney--pathology<br/>Life Tables<br/>Liver--pathology<br/>Male<br/>Melphalan--administration & dosage<br/>Middle Aged<br/>Myocardium--pathology<br/>Nervous System--pathology<br/>Paraproteins--analysis<br/>Platelet Transfusion<br/>Prognosis<br/>Recurrence<br/>Severity of Illness Index<br/>Survival Analysis<br/>Transplantation Conditioning<br/>Treatment Outcome